LivaNova names Stefano Folli to head cardiopulmonary unit
LivaNova PLC announced that Stefano Folli will join the company as President of its Cardiopulmonary business unit, effective June 1. He will succeed Franco Poletti, who is retiring on July 31, with a transition period expected over several months. Folli, who previously held leadership roles at Philips, will oversee the strategic growth of the nearly $800 million business.
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova PLC has appointed Stefano Folli as the incoming President of its Cardiopulmonary business unit, effective June 1, 2026. Folli will succeed Franco Poletti, who is set to retire on July 31, and will oversee the strategic growth of the nearly $800-million business. With over three decades of experience, including leadership roles at Philips, Folli aims to strengthen execution, accelerate innovation, and advance patient outcomes in LivaNova's Cardiopulmonary division.
LivaNova PLC stock (US5356991077): cardiac device specialist in focus after regulatory update and earnings
LivaNova PLC is gaining investor attention after an FDA panel supported an update to its heart pump controller software and the company reported strong first-quarter 2026 results. The medical device company, specializing in cardiovascular and neuromodulation devices, saw continued growth in neuromodulation and cardiopulmonary product sales. US investors are closely tracking LivaNova's performance due to its exposure to the US healthcare system and the critical nature of ongoing regulatory approvals and reimbursement decisions.
LivaNova’s SWOT analysis: medical device stock eyes growth plan
LivaNova (NASDAQ:LIVN), a medical technology company, has outlined an ambitious five-year strategic plan for growth, driven by strong quarterly performance in its cardiopulmonary support and epilepsy segments. The plan includes pursuing high single-digit sales growth, achieving high-20 percent operating margins, and launching an obstructive sleep apnea system by 2027, representing a significant market opportunity. While potential delays and competitive pressures pose risks, the company's strong core business momentum and high gross profit margin underscore its growth potential.
LivaNova to present at Goldman Sachs Global Healthcare Conference in June
LivaNova PLC, a global medical technology and innovation company, announced it will participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in June. The company's management is scheduled to present on Tuesday, June 10, 2026. This presentation offers an opportunity for LivaNova to update investors and the healthcare community on its latest developments and strategies.
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LivaNova PLC announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Phil Kowalczyk will present at a fireside chat on June 8, 2026, at 8 a.m. EDT. The discussion will be webcast live and a replay will be available on the company's website for interested parties.
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June 2026
LivaNova PLC (Nasdaq: LIVN) announced it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026, at 8 a.m. EDT. The discussion will feature CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Phil Kowalczyk. A webcast of the event will be accessible via LivaNova's website, with a replay available within 24 hours.
Will LivaNova's (LIVN) Return to Quarterly Profitability Reset Investor Expectations on Its Turnaround Narrative?
LivaNova PLC (LIVN) recently reported Q1 2026 results, showing a significant turnaround from a net loss to a net income of US$22.29 million and positive earnings per share. This return to profitability, alongside FDA approval for its aura6000 System, could reshape investor expectations regarding the company's growth trajectory and its ability to translate clinical wins into durable earnings despite ongoing industry pressures. The article suggests this strengthens the short-term investment thesis but warns of continued risks related to reimbursement and high R&D spending.
Will LivaNova's (LIVN) Return to Quarterly Profitability Reset Investor Expectations on Its Turnaround Narrative?
LivaNova PLC reported a return to profitability in Q1 2026, with sales up to US$362.26 million and net income of US$22.29 million, replacing a prior-year net loss. This marks a significant improvement in profitability and cost control, potentially reshaping the investment narrative for the company. The FDA's PMA approval for the aura6000 System also adds a new growth driver, though reimbursement and R&D intensity remain key risks.
LivaNova PLC stock (US5356991077): cardiac device maker updates investors after latest earnings
LivaNova PLC, a medical technology company specializing in cardiac surgery and neuromodulation, has attracted investor attention following its latest quarterly results and business outlook updates. The article details the company's core business model, key revenue drivers from cardiopulmonary and neuromodulation products, and its competitive position in heavily regulated markets. It also highlights the relevance of LivaNova for US investors due to its Nasdaq listing and exposure to the US healthcare system, while discussing inherent risks like regulatory compliance and reimbursement challenges.
LivaNova PLC - Ordinary Shares (NQ: LIVN) Stock Quote and News
This article provides a detailed stock quote and recent news for LivaNova PLC (NASDAQ: LIVN). It includes current trading information, performance metrics over various periods, and a chronological list of recent news, including earnings reports, clinical study results, and FDA approvals. The article also answers frequently asked questions about the company's publicly traded status and market capitalization.
Total debt per share of LivaNova Plc – SWB:LIA
This article provides financial data for LivaNova Plc (SWB:LIA), specifically focusing on its total debt per share. It mentions the market status as closed with no trades and indicates that data is provided by ICE Data Services and FactSet. The content is primarily a data placeholder from TradingView, displaying a table for debt per share values over different periods.
ETFs Investing in LivaNova Plc Stocks
This article lists various ETFs that hold LivaNova Plc (LIA) stocks, providing detailed financial data for each fund, including market value, weight of LIA, issuer, management style, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover different market segments such as small-cap, mid-cap, extended market, and health care, offering investors diverse options with varying risk profiles.
LivaNova stock (US5356991077): Medical device leader with Nasdaq listing
LivaNova PLC is a London-headquartered medical technology firm listed on Nasdaq, specializing in neuromodulation and cardiovascular solutions. The company's stock recently traded higher at $71.75, showing a daily gain of 2.37%, driven by its Vagus Nerve Stimulation (VNS) Therapy system for drug-resistant epilepsy. LivaNova's Nasdaq listing and focus on innovative medical devices provide US investors direct exposure to a global medtech player tackling significant health challenges.
Understanding Momentum Shifts in (LIVN)
This article analyzes Livanova Plc (LIVN) with a focus on momentum shifts, identifying a strong overweight bias across all time horizons. It outlines distinct trading strategies, including position trading, momentum breakout, and risk hedging, based on AI model analysis. The report highlights an exceptional 27.3:1 risk-reward short setup and provides multi-timeframe signal analysis for support and resistance levels.
LivaNova (LIVN) Stock Forum and Discussion
This article provides a discussion forum for LivaNova (LIVN) stock, allowing investors and interested parties to share insights and opinions. The content is primarily a placeholder for user-generated discussions regarding the company's performance and future outlook.
Why LivaNova (LIVN) Is Up 18.0% After Boosting 2026 Outlook And Winning Aura6000 FDA Approval
LivaNova (LIVN) saw an 18.0% stock increase after reporting strong first-quarter 2026 results, boosting its full-year guidance, and securing FDA approval for its aura6000 System for obstructive sleep apnea. This approval expands the company's neuromodulation portfolio. The article discusses LivaNova's investment narrative, including projected revenue and earnings by 2029, and highlights potential upsides and risks like reimbursement pressure.
LivaNova PLC 1Q 2026: Revenue $362.26M, EPS $0.4— 10-Q Summary
LivaNova PLC reported strong first-quarter 2026 results, with revenue increasing by 14.3% year-over-year to $362.26 million. The company achieved diluted EPS of $0.4, a significant improvement from a loss in 1Q 2025, and returned to a net income of $22.29 million. Revenue growth was driven by broad-based demand across channels and regions, particularly in Cardiopulmonary and Neuromodulation segments.
LivaNova (LIVN) Q1 2025 Earnings Transcript
LivaNova (LIVN) reported strong Q1 2025 results with 10% organic revenue growth, driven by Cardiopulmonary and Neuromodulation segments. The company raised its full-year organic revenue growth guidance to 7-8% and provided updates on the resolution of the SNIA litigation and the positive 12-month data from its OSPREY trial for obstructive sleep apnea. Management also addressed the impact of tariffs, indicating they would be manageable, and discussed the updated outlook for their Epilepsy and Difficult-to-Treat Depression businesses.
LivaNova PLC (NASDAQ:LIVN) Q1 2026 Earnings Call Transcript
LivaNova PLC reported strong Q1 2026 earnings, with 11% revenue growth driven by cardiopulmonary and epilepsy businesses. The company raised its full-year 2026 revenue guidance to 7-8% growth and adjusted EPS to $4.20-$4.30, citing significant progress in its Obstructive Sleep Apnea (OSA) program, including FDA approval for the aura6000 system, and favorable U.S. Medicare reimbursement changes for VNS therapy in epilepsy. LivaNova also highlighted ongoing investments in innovation and manufacturing capacity to sustain long-term growth and market share gains.
LivaNova: Q1 Earnings Snapshot
LivaNova PLC reported Q1 earnings of $22.3 million, or 40 cents per share, with adjusted earnings of 98 cents per share. The medical technology company achieved revenue of $362.3 million in the first quarter. LivaNova anticipates full-year earnings to be in the range of $4.20 to $4.30 per share.
[IRANNOTICE] LivaNova PLC SEC Filing
LivaNova PLC has filed an IRANNOTICE with the SEC, disclosing information required under the Iran Threat Reduction and Syria Human Rights Act and the Securities Exchange Act of 1934. This disclosure is contained within its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The filing indicates a neutral impact and sentiment according to Stock Titan.
LivaNova (NASDAQ: LIVN) returns to profit as Q1 2026 revenue climbs
LivaNova (NASDAQ: LIVN) reported a significant return to profit in Q1 2026, with net income of $22.3 million compared to a net loss of $327.3 million in the prior year, driven by a 14.3% revenue increase to $362.3 million. Both Cardiopulmonary and Neuromodulation segments showed growth, though Neuromodulation's segment income was impacted by higher R&D and contingent consideration expenses. The company also received FDA Premarket Approval for its aura6000 System for obstructive sleep apnea.
Earnings call transcript: LivaNova PLC beats Q1 2026 estimates, shares rise
LivaNova PLC reported better-than-expected Q1 2026 earnings, with an adjusted EPS of $0.98 against a forecast of $0.90, and revenue hitting $362.3 million over the anticipated $346.06 million. This strong performance, driven by gains in cardiopulmonary and epilepsy segments, led to a 6.34% rise in premarket trading and an increased full-year revenue growth guidance of 7-8%. The company highlighted strategic advancements in Obstructive Sleep Apnea (OSA) with FDA approval for the aura6000 System and progress in its next-generation oxygenator and VNS Therapy for difficult-to-treat depression.
LivaNova Releases Q1 2026 Financial Results
LivaNova PLC surpassed Wall Street expectations in Q1 2026, reporting adjusted diluted earnings per share of $0.98, exceeding the $0.91 consensus estimate. The medical technology company's revenue increased by 14.3% year-over-year to $362.3M, driven significantly by its Cardiopulmonary segment. Management projects full-year 2026 adjusted EPS to be between $4.20 and $4.30, with analysts maintaining a favorable view of the stock.
Earnings Flash (LIVN) LivaNova PLC Posts Q1 Adjusted EPS $0.98 per Share, vs. FactSet Est of $0.90
LivaNova PLC (LIVN) announced its Q1 adjusted EPS was $0.98 per share, surpassing FactSet's estimate of $0.90. The medical technology company specializes in cardiopulmonary and neuromodulation products, including devices for obstructive sleep apnea and epilepsy. The article highlights recent clinical study results and FDA approvals for some of its key products.
LivaNova: Q1 Earnings Snapshot
LivaNova PLC reported earnings of $22.3 million in its first quarter, translating to 40 cents per share. Adjusted earnings were 98 cents per share, and the medical technology company posted revenue of $362.3 million. LivaNova anticipates full-year earnings between $4.20 and $4.30 per share.
LivaNova plc (LIVN) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY26 EPS Guidance
LivaNova plc (LIVN) reported strong first-quarter results, surpassing analyst estimates with an EPS of $0.98, $0.08 higher than anticipated, and revenues of $362.3 million, exceeding the consensus of $346.06 million. The company also provided its full-year 2026 EPS guidance, projecting between $4.20 and $4.30, aligning closely with analyst expectations.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC announced strong first-quarter 2026 results, reporting double-digit revenue growth and raising its full-year 2026 revenue and adjusted diluted earnings per share guidance. The company also achieved a significant milestone with U.S. FDA premarket approval for its aura6000 System to treat moderate to severe obstructive sleep apnea, positioning it for growth in a high-margin market. This performance was driven by strong execution in Cardiopulmonary and Neuromodulation businesses and strategic advancements in OSA.
LivaNova earnings ahead as reimbursement tailwinds build By Investing.com
LivaNova PLC is set to report its first-quarter earnings, with analysts anticipating 90 cents per share on revenue of $346.1 million. The focus will be on whether recent regulatory and reimbursement advancements, such as higher VNS Therapy reimbursement and FDA approval for the aura6000 System, will translate into accelerated growth. Investors will also monitor if a projected seasonal revenue decline indicates underlying weakness or normal patterns.
LIVN SEC Filings - Livanova Plc 10-K, 10-Q, 8-K Forms
This page provides access to U.S. SEC filings for LivaNova PLC (LIVN), a global medical technology company, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Stock Titan enhances these filings with AI‑powered summaries that explain key points and provide real‑time updates from the EDGAR system. The most recent filing reported an insider sale where Francesco Bianchi disposed of 1,500 LIVN shares on August 25, 2025.
Avoiding Lag: Real-Time Signals in (LIVN) Movement
The article analyzes Livanova Plc (LIVN) using AI, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It identifies elevated downside risk due to a lack of additional long-term support signals and provides three distinct institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over
LivaNova PLC (LIVN) shares recently fell by 3.3%, bringing its price to $61.29, which is considered slightly overvalued by 0.1% according to GuruFocus' GF Value estimate. Despite this slight overvaluation, the company boasts a strong GF Score of 80/100, driven primarily by high momentum, though profitability shows room for improvement. The current forward P/E ratio of 14.6x is significantly lower than its historical 5-year median, suggesting a unique opportunity despite the current GF Value assessment.
Will OSPREY Trial Data on aura6000 Sleep Apnea Device Change LivaNova's (LIVN) Narrative
LivaNova's (LIVN) OSPREY trial data, recently published in the Annals of Internal Medicine, showed sustained safety and improved outcomes for its aura6000 sleep apnea device, especially in high-risk patients. This strengthens the investment narrative around aura6000, aligning with its recent FDA approval, but investors should also consider the impact of ongoing high R&D and commercialization costs on margins and the challenges of timely revenue generation. While some analysts have bullish revenue expectations, the success hinges on effective commercialization and reimbursement.
Peregrine Capital Management LLC Invests $3.83 Million in LivaNova PLC $LIVN
Peregrine Capital Management LLC has initiated a new position in LivaNova PLC (NASDAQ:LIVN), purchasing 62,242 shares valued at approximately $3.83 million. Other major institutional investors have also increased their stakes in LivaNova, bringing institutional ownership to about 97.64% of the stock. The company recently exceeded quarterly estimates and holds a "Moderate Buy" consensus rating from analysts with an average target price of $74.78.
Discipline and Rules-Based Execution in LIVN Response
This article analyzes Livanova Plc (NASDAQ: LIVN) with a strong overweight bias based on sentiment across all horizons. It highlights an exceptional 32.7:1 risk-reward setup targeting a 9.4% gain with a 0.3% risk. The piece outlines three AI-generated institutional trading strategies for LIVN: Position Trading, Momentum Breakout, and Risk Hedging, along with a multi-timeframe signal analysis.
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
LivaNova PLC announced that the Annals of Internal Medicine published the full 12-month data from its OSPREY randomized controlled trial. The study evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS) delivered by LivaNova’s aura6000™ System for moderate to severe Obstructive Sleep Apnea (OSA), demonstrating clinically significant and sustained improvements. This rigorous RCT provides strong evidence for pHGNS as a competitive treatment option, showing improvements in AHI, sleep quality, and patient-reported outcomes with an acceptable safety profile.
LivaNova PLC stock (US5356991077): Why does its medtech innovation edge matter more now?
LivaNova PLC, a medtech company specializing in cardiovascular and neuromodulation products, is positioned for steady growth due to increased demand for advanced medical solutions. Its portfolio focuses on high-margin, life-saving devices for heart and brain conditions, addressing critical healthcare needs driven by aging populations and rising chronic diseases. The company's niche leadership, coupled with strong reimbursement dynamics in English-speaking markets, makes its stock a compelling option for investors seeking resilient healthcare plays.
Tissue Heart Valves Market Key Companies Analysis - Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, LivaNova, CryoLife, JenaValve Technology, Sorin Group, Colibri Heart Valve etc.
The global tissue heart valves market is projected to grow at a CAGR of 4.0% from 2025 to 2031, driven by the increasing prevalence of cardiovascular diseases, advancements in valve replacement technologies, and the aging global population. Key market players like Edwards Lifesciences, Medtronic, and Abbott are focusing on product innovation and strategic initiatives to strengthen their market presence. The report from The Insight Partners highlights opportunities in emerging regions and the preference for tissue valves in certain patient groups due to reduced anticoagulation risks.
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of "Moderate Buy" from Analysts
LivaNova PLC (NASDAQ:LIVN) has received an average "Moderate Buy" rating from analysts, with ten firms covering the stock and an average one-year price target of $74.78. The company's recent quarterly earnings beat expectations with an EPS of $0.86 and revenue of $360.9 million, and it issued a positive FY2026 EPS guidance. Institutional investors show significant interest, owning 97.64% of the stock and increasing their stakes.
33,332 Shares in LivaNova PLC $LIVN Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL has acquired a new position of 33,332 shares in LivaNova PLC, valued at approximately $1.746 million, making institution investors collectively own 97.64% of the stock. LivaNova recently exceeded quarterly expectations with an EPS of $0.86 and revenue of $360.9 million, forecasting a FY2026 EPS of 4.15–4.25. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $74.78.
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN
Aberdeen Group plc significantly reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 89.5% in the fourth quarter, selling 220,443 shares and retaining 25,850 shares valued at $1.591 million. Despite this, several other institutional investors, including Artisan Partners, Wellington Management, Invesco, and Millennium Management, substantially increased their positions, bringing institutional ownership to 97.64%. LivaNova also reported stronger-than-expected Q4 results and received a "Moderate Buy" consensus rating with an average price target of $74.78 from analysts.
Behavioral Patterns of LIVN and Institutional Flows
This article from Stock Traders Daily provides an AI-generated analysis of Livanova Plc (NASDAQ: LIVN), indicating a neutral near- and mid-term outlook that could moderate a long-term positive bias. It highlights a significant 32.7:1 risk-reward setup, targeting a 9.5% gain against a 0.3% risk, and presents specific institutional trading strategies across different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging.
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN
Allspring Global Investments Holdings LLC reduced its stake in LivaNova PLC (LIVN) by 8.9% in Q4 2026, selling 19,629 shares and now owning 201,832 shares valued at $12.42 million. Despite this reduction, other institutional investors have increased their holdings, and LivaNova reported strong Q4 earnings, beating expectations with $0.86 EPS and revenue of $360.92 million. The stock holds a "Moderate Buy" consensus rating with an average price target of $74.78.
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
Exchange Traded Concepts LLC recently acquired 15,768 shares of LivaNova PLC, valued at approximately $970,000, during the fourth quarter. This acquisition is part of a trend where institutional investors now own 97.64% of the company's stock. LivaNova PLC exceeded its Q4 earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $74.78.
(LIVN) Movement Within Algorithmic Entry Frameworks
Livanova Plc (NASDAQ: LIVN) shows weak near-term sentiment while maintaining long-term strength, with no clear price positioning identified and elevated downside risk. Algorithmic models provide three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. Multi-timeframe analysis reveals divergent sentiment, suggesting choppy conditions with weak near-term and strong long-term signals.
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN
Tudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC
Tudor Investment Corp ET AL has acquired a new stake of 33,332 shares in LivaNova PLC for approximately $1.75 million, representing 0.06% ownership. This investment signals the hedge fund's confidence in LivaNova's growth potential and its innovative cardiac and neuromodulation solutions. The acquisition highlights the continued interest from institutional investors in the medical technology sector.
How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors
The FDA's premarket approval of LivaNova's aura6000 System for obstructive sleep apnea is expected to significantly impact the company's investment narrative, strengthening its neuromodulation portfolio. While this approval offers a new growth driver, investors should also consider the potential risks associated with slower commercialization or higher-than-expected launch costs, which could affect the company's ability to meet its 2026 revenue guidance and profitability targets. The article highlights LivaNova's projected revenue of $1.7 billion and earnings of $173.6 million by 2029, suggesting a fair value upside for LIVN stock.
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea
LivaNova PLC (NASDAQ:LIVN) announced that the FDA has granted premarket approval for its aura6000 System, designed for adults with moderate to severe obstructive sleep apnea who cannot use or respond to other therapies. This approval follows positive Q4 results, with the company reporting adjusted EPS of 86c and revenue of $360.9M. Analysts have raised price targets for LivaNova, citing a strong outlook for 2026.
